First Results From Editas CRISPR Eye Therapy Underwhelm Investors
Safety Is Reassuring But Efficacy Unclear
While rivals Intellia impressed with their first in vivo CRISPR gene-editing data, Editas’s first results in just two patients are not enough to convince investors.
You may also be interested in...
Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE
Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.
CRISPR Patent Ruling Lifts Editas, Disappoints Intellia and CRISPR Therapeutics
A US decision to grant a CRISPR Cas9 patent to The Broad Institute lifts Editas but adds uncertainty to the IP estate of Intellia and CRISPR Therapeutics.
Gene-Editing Companies To Watch At J.P. Morgan
Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.